Trial Profile

A Phase 2 proof of concept study of RLYB116 in immune PTR.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RLYB 116 (Primary)
Indications Blood platelet disorders
Focus Proof of concept; Therapeutic Use

Most Recent Events

23 Feb 2026 New trial record
17 Feb 2026 According to Rallybio media release, company is planning for Initiation of RLYB116 proof of concept Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness Currently Planned for 2H 2026 with Potential for Topline Data in 2027 .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com